Login
$KROS
$10.18 -$0.12 (1.17%) Live

$KROS SEC Filings

Filed On Filing
12 Nov 2026 144
05 Nov 2026 8-K: Regulation FD Disclosure

Corporate Presentation Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Wor...

05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

LEXINGTON, Mass., November 5, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a...

27 Oct 2026 SCHEDULE 13G/A
29 Sep 2026 8-K: Regulation FD Disclosure

LEXINGTON, Mass., September 29, 2026, (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of...

28 Sep 2026 8-K: Regulation FD Disclosure

LEXINGTON, Mass., September 28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of ...

16 Sep 2026 EFFECT
11 Sep 2026 DEL AM
10 Sep 2026 S-3
08 Sep 2026 8-K: Other Events

LEXINGTON, Mass., September 8, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat ...

20 Aug 2026 Form 4: Tanini Annita, Corp. Controller & VP, Finance

Sold 1,224 shares ($12.6K)

20 Aug 2026 Form 4: Lerner Lorena Raquel, Chief Scientific Officer

Sold 3,568 shares ($36.7K)

20 Aug 2026 Form 4: Cho Esther, Chief Legal Officer

Sold 4,485 shares ($46.2K)

20 Aug 2026 Form 4: Newton Charles W., Director

Sold 551 shares ($5.68K)

19 Aug 2026 Form 4: Bienaime Jean Jacques, Director

Bought 1,000 shares ($10.3K)

18 Aug 2026 144
13 Aug 2026 Form 3: Tanini Annita, Corp. Controller & VP, Finance

Holds 46,368 shares of Common Stock

03 Aug 2026 8-K: Regulation FD Disclosure

Corporate Presentation Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Wor...

03 Aug 2026 10-Q

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support